Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: A systematic review of randomized trial data

Transplantation

Volumn 81, Issue 7, 2006, Pages 953-965

  Webster, Angela C ^a,b,d   Pankhurst, Tanya ^c   Rinaldi, Fiona ^a   Chapman, Jeremy R ^b   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Acute rejection; Kidney transplantation; Meta analysis; Monoclonal antibody; Polyclonal antibody

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OKT 3; POLYCLONAL ANTIBODY; PREDNISOLONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEVER; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALAISE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; REPRODUCIBILITY; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIBODIES; ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33646384606     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000215178.72344.9d     Document Type: Review

References (44)

1. Immunosuppression. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. Ann Arbor: HHS/HRSA/OSP/DOT and UNOS, 2004.
2. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326(7393): 789.
3. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews 2004; (1): CD003897.
4. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331(7520): 810.
5. Jamil B, Nicholls K, Becker GJ, Walker RG. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999; 68(10): 1597-1603.
6. Joseph JT, Kingsmore DB, Junor BJ, et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant 2001; 15(4): 221-227.
7. Leggat JE, Jr., Ojo AO, Leichtman AB, et al. Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodes. Transplantation 1997; 63(9): 1268-1272.
8. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study. Transplant Proc 1997; 29(1-2): 73-76.
9. Kreis H. Antilymphocyte globulins in kidney transplantation. Kidney Int 1992; 38: S188-S192.
10. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001; 72(12): S89-S93.
11. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309(6964): 1286-1291.
12. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
13. Baldi A, Malaise J, Mourad M, Squifflet JP. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results. Transplant Proc 2000; 32(2): 429-431.
14. Barenbrock M, Spieker C, Buchholz B, et al. Cardiovascular effects of the rejection therapy with antibodies against lymphocytes. Nieren-und Hochdruckkrankheiten 1994; 23: 84-87.
15. Birkeland SA. A controlled clinical trial of treatment with ALG in established rejection of renal allografts. Acta Med Scand 1975; 198(6): 489-496.
16. Casadei D, Rial M, Argento J, et al. Preliminary results from a randomized and prospective study of high-dose immunoglobulin versus monoclonal antibody in the rescue of steroid-resistant rejections. Transplant Proc 1998; 30(5): 2164.
17. Filo RS, Smith EJ, Leapman SB. Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin. Transplantation 1980; 30(6): 445-449.
18. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66(1): 29-37.
19. Glass NR, Miller DT, Sollinger HW, Belzer FO. A comparative study of steroids and heterologous antiserum in the treatment of renal allograft rejection. Transplant Proc 1983; 15(1): 617-621.
20. Goldstein G, Schindler J, Tsai H, et al. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337-342.
21. Hesse UJ, Wienand P, Baldamus C, Arns W. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period. Transplant Proc 1990; 22(5): 2273-2274.
22. Hilbrands LB, Hoitsma AJ, Koene RA. Methylpredenisolone versus ATG as initial treatment for acute rejections after renal transplantation [abstract]. Nephrol Dial Transplant 1996; 11(8): 1675.
23. Hoitsma AJ, Reekers P, Kreeftenberg JG, et al. Treatment of acute rejection of cadaveric renal allografts with rabbit antithymocyte globulin. Transplantation 1982; 33(1): 12-16.
24. Hourmant M, Soulillou JP, Remi JP, et al. Use of cyclosporin A after antilymphocyte serum in renal transplantation [French]. Presse Medicale 1985; 14(41): 2093-2096.
25. Howard RJ, Condie RM, Sutherland DE, et al. The use of antilymphoblast globulin in the treatment of renal allograft rejection: a double-blind, randomized study. Transplantation 1977; 24(6): 419-423.
26. Johnson K, Niblack G, Richie R, et al. Multicenter comparison of rejection reversal: rabbit anti-human lymphocyte serum (ATS) versus horse anti-human lymphocyte globulin (ATGAM). Transplant Proc 1989; 21(1 Pt 2): 1734-1735.
27. Mariat C, Alamartine E, Diab N, et al. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transplant Int 1998; 11(3): 231-236.
28. Midtvedt K, Tafjord AB, Hartmann A, et al. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection. Transplantation 1996; 62(1): 38-42.
29. Midtvedt K, Fauchald P, Lien B, et al. Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection. Clin Transplant 2003; 17(1): 69-74.
30. Shield CFI, Cosimi BA, Tolkoff RN, et al. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 1979; 28: 461-464.
31. Streem SB, Novick AC, Braun WE, et al. Low-dose maintenance prednisone and antilymphoblast globulin for the treatment of acute rejection. A steroid-sparing approach to immunosuppressive therapy. Transplantation 1983; 35(5): 420-424.
32. Theodorakis J, Schneeberger H, Illner WD, et al. Aggressive treatment of the first acute rejection episode using first-line anti-lymphocytic preparation reduces further acute rejection episodes after human kidney transplantation. Transplant Int 1998; 11 Suppl 1: S86-S89.
33. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53(1): 80-86.
34. Egger M. Problems and limitations in conducting systematic reviews. In: Egger M, ed. Systematic reviews in health care. London: BMJ books, 2001:43-68.
35. Peduzzi P, Wittes J, Detre K, Holford T. Analysis as-randomized and the problem of non-adherence: an example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery. Stat Med 1993; 12(13): 1185-1195.
36. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979; 301(26): 1410-1412.
37. Hollis S, Campbell F. What is meant by intention to treat analysis? BMJ 1999; 319(7211): 670-674.
38. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clinical Pharmacology 2001; 1(1): 3.
39. Cuervo LG, Clarke M. Balancing benefits and harms in health care. BMJ 2003; 327(7406): 65-66.
40. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials; increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290(12): 1624-1632.
41. National Institute for Clinical Excellence. Immunosuppressive therapy for renal transplantation in adults. Technology Appraisal Guidance 85. 2004. London, UK, National Institute for Clinical Excellence. Technology Appraisal Guidance.
42. Excell L, Chadban S, McDonald S. Transplantation. ANZDATA Registry Report 2004. Adelaide: Australian and New Zealand dialysis and transplant registry, 2003: 90.
43. Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997; 8(11): 1771-1777.
44. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. Ann Int Med 1998; 128(10): 817-826.